NuChem Sciences Inc.

NuChem Sciences Inc. is a asset manager based in Saint-Laurent; the Altss profile covers its classification, headquarters, registration, AUM band, and key...

NuChem Sciences Inc.

Sygnature Discovery is a world-leading integrated drug discovery CRO based in the UK and Canada with headquarters in Nottingham (UK).

Website

www.nuchemsciences.com

General information

Firm type

Asset Manager

Location

Region

North America

Country

Canada

City

Saint-Laurent

Corporate office

201-2350 Cohen, Saint-Laurent, Quebec H4R 2N6, Canada

Additional offices

Nottingham, UK · Alderley Park, UK · Glasgow, UK · Tytherington, UK · Lévis, Canada

Does NuChem Sciences invest in drug development or only provide services?

NuChem Sciences provides contract research services only. Sygnature Discovery states it has no internal drug pipeline, meaning the firm does not invest its own capital in developing drugs. Instead, it charges fees for preclinical discovery services across multiple therapeutic areas.

What services does NuChem Sciences offer?

NuChem Sciences (via Sygnature Discovery) offers integrated drug discovery services including computer-aided drug design, protein science, bioscience, chemistry, drug metabolism and pharmacokinetics, in vivo pharmacology, and formulation development. The firm claims expertise across oncology, neuroscience, anti-infectives, and metabolic, inflammatory, fibrotic, and respiratory diseases.

Where are NuChem Sciences' offices located?

NuChem Sciences maintains two Canadian offices: one in Saint-Laurent, Quebec (201-2350 Cohen) and one in Lévis, Quebec (480 rue Perreault). The parent company Sygnature Discovery has UK offices in Nottingham (HQ), Alderley Park, Glasgow, and Tytherington.

Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: Jun 3, 2026. Continuous refresh with full update cycles at least every 30 days.